{"id":"https://openalex.org/W4408935709","doi":"https://doi.org/10.2337/figshare.28473485.v1","title":"Cardiovascular, Kidney Outcomes and Mortality with Long-Acting Injectable and Oral Glucagon-Like Peptide-1 Receptor Agonists in Persons With Type 2 Diabetes \u2013 a Systematic Review and Meta-Analyses of Randomized Trials","display_name":"Cardiovascular, Kidney Outcomes and Mortality with Long-Acting Injectable and Oral Glucagon-Like Peptide-1 Receptor Agonists in Persons With Type 2 Diabetes \u2013 a Systematic Review and Meta-Analyses of Randomized Trials","publication_year":2025,"publication_date":"2025-03-29","ids":{"openalex":"https://openalex.org/W4408935709","doi":"https://doi.org/10.2337/figshare.28473485.v1"},"language":"en","primary_location":{"id":"doi:10.2337/figshare.28473485.v1","doi":"https://doi.org/10.2337/figshare.28473485.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.28473485.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.2337/figshare.28473485.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061857615","display_name":"Matthew M.Y. Lee","orcid":"https://orcid.org/0000-0001-9213-2067","observed_orcids":["https://orcid.org/0000-0001-9213-2067"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew M.Y. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078498803","display_name":"Naveed A. Sattar","orcid":"https://orcid.org/0000-0002-1604-2593","observed_orcids":["https://orcid.org/0000-0002-1604-2593"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naveed Sattar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018561083","display_name":"Rodica Pop\u2010Busui","orcid":"https://orcid.org/0000-0002-2042-1350","observed_orcids":["https://orcid.org/0000-0002-2042-1350"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rodica Pop-Busui","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039316946","display_name":"John Eric Deanfield","orcid":"https://orcid.org/0000-0001-8806-6052","observed_orcids":["https://orcid.org/0000-0001-8806-6052"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Deanfield","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090993994","display_name":"Scott S. Emerson","orcid":"https://orcid.org/0000-0002-2695-0165","observed_orcids":["https://orcid.org/0000-0002-2695-0165"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott S. Emerson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005006476","display_name":"Silvio E. Inzucchi","orcid":"https://orcid.org/0000-0003-1254-6636","observed_orcids":["https://orcid.org/0000-0003-1254-6636"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Silvio E. Inzucchi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043842967","display_name":"Johannes F.E. Mann","orcid":"https://orcid.org/0000-0002-3154-5332","observed_orcids":["https://orcid.org/0000-0002-3154-5332"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johannes F.E. Mann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019976194","display_name":"Nikolaus Marx","orcid":"https://orcid.org/0000-0001-6141-634X","observed_orcids":["https://orcid.org/0000-0001-6141-634X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nikolaus Marx","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025608840","display_name":"Sharon L. Mulvagh","orcid":"https://orcid.org/0000-0002-7377-4053","observed_orcids":["https://orcid.org/0000-0002-7377-4053"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sharon L. Mulvagh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072011562","display_name":"Neil R Poulter","orcid":"https://orcid.org/0000-0002-6292-997X","observed_orcids":["https://orcid.org/0000-0002-6292-997X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil R. Poulter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075474387","display_name":"Sunil V. Badve","orcid":"https://orcid.org/0000-0003-2269-312X","observed_orcids":["https://orcid.org/0000-0003-2269-312X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sunil V. Badve","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059098934","display_name":"Richard E. Pratley","orcid":"https://orcid.org/0000-0002-2912-1389","observed_orcids":["https://orcid.org/0000-0002-2912-1389"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard E. Pratley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027520502","display_name":"Vlado Perkovic","orcid":"https://orcid.org/0000-0002-4257-7620","observed_orcids":["https://orcid.org/0000-0002-4257-7620"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vlado Perkovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040182038","display_name":"John B. Buse","orcid":"https://orcid.org/0000-0002-9723-3876","observed_orcids":["https://orcid.org/0000-0002-9723-3876","https://orcid.org/0000-0001-6894-4110"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John B. Buse","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5071945904","display_name":"Darren K. McGuire","orcid":"https://orcid.org/0000-0002-6412-7989","observed_orcids":["https://orcid.org/0000-0002-6412-7989"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Darren K. McGuire","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9480000138282776},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9589999914169312},{"id":"https://openalex.org/keywords/oral-semaglutide","display_name":"oral semaglutide","score":0.8450000286102295},{"id":"https://openalex.org/keywords/cardiovascular-outcomes","display_name":"cardiovascular outcomes","score":0.7540000081062317},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.9490000009536743},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.9419999718666077},{"id":"https://openalex.org/keywords/heart-failure-hospitalization","display_name":"heart failure hospitalization","score":0.9210000038146973},{"id":"https://openalex.org/keywords/renal-outcomes","display_name":"renal outcomes","score":0.8199999928474426},{"id":"https://openalex.org/keywords/kidney-failure","display_name":"renal failure","score":0.746999979019165},{"id":"https://openalex.org/keywords/estimated-glomerular-filtration-rate-decline","display_name":"estimated glomerular filtration rate decline","score":0.9010000228881836},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5630000233650208},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8309999704360962},{"id":"https://openalex.org/keywords/retinopathy","display_name":"retinopathy","score":0.7070000171661377},{"id":"https://openalex.org/keywords/pancreatic-cancer-risk","display_name":"pancreatic cancer risk","score":0.597000002861023}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7165504693984985},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6738377809524536},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6152226328849792},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.5651794672012329},{"id":"https://openalex.org/C189708586","wikidata":"https://www.wikidata.org/wiki/Q1504425","display_name":"Systematic review","level":3,"score":0.5037223696708679},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4956275224685669},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.49402791261672974},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4891400635242462},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.47212108969688416},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3778074383735657},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36859145760536194},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3305049538612366},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.28381282091140747},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14349991083145142},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.12508291006088257},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.05855560302734375}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/figshare.28473485.v1","doi":"https://doi.org/10.2337/figshare.28473485.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.28473485.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.2337/figshare.28473485.v1","doi":"https://doi.org/10.2337/figshare.28473485.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.28473485.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4408960968","https://openalex.org/W3195404919","https://openalex.org/W4396691213","https://openalex.org/W3008568962","https://openalex.org/W2968073288","https://openalex.org/W4404685978","https://openalex.org/W2964932552","https://openalex.org/W3200446817","https://openalex.org/W4200182994","https://openalex.org/W4405988757"],"abstract_inverted_index":{"BACKGROUND:":[0],"Glucagon-like":[1],"peptide-1":[2],"receptor":[3],"agonists":[4],"(GLP-1RAs)":[5],"reduce":[6,240],"major":[7],"adverse":[8],"cardiovascular":[9,45],"events":[10,247],"(MACE)":[11],"in":[12,63,248],"type":[13],"2":[14],"diabetes":[15],"(T2D),":[16],"although":[17],"it":[18],"remains":[19],"unclear":[20],"if":[21],"benefits":[22,48],"extend":[23],"to":[24,58],"both":[25,235],"subcutaneous":[26],"and":[27,41,46,49,137,173,223,237,245],"oral":[28,238],"formulations.":[29],"PURPOSE":[30],"These":[31],"meta-analyses,":[32],"including":[33,234],"new":[34],"data":[35],"from":[36],"the":[37,174],"SOUL":[38],"(oral":[39],"semaglutide)":[40],"FLOW":[42],"trials,":[43],"examined":[44],"kidney":[47,112,135,176,246],"risks":[50,208],"of":[51,69,82,209],"long-acting":[52,146,232],"(defined":[53],"as":[54],"having":[55],"pharmacokinetics":[56],"sufficient":[57],"provide":[59],"24-hour":[60],"activity)":[61],"GLP-1RAs":[62,83,147],"T2D.":[64,88,249],"DATA":[65,89,140],"SOURCES":[66],"Systematic":[67],"review":[68],"PubMed":[70],"(to":[71],"Feb":[72],"07,":[73],"2025).":[74],"PROSPERO:":[75],"CRD42024607253.":[76],"STUDY":[77],"SELECTION":[78],"Randomized":[79],"placebo-controlled":[80],"CVOTs":[81],"with":[84,87],"\u2265500":[85],"individuals":[86],"EXTRACTION":[90],"A":[91],"random":[92],"effects":[93],"model":[94],"estimated":[95],"hazard":[96],"ratios":[97],"(HR)":[98],"for":[99,106],"MACE;":[100],"its":[101],"components;":[102],"all-cause":[103,158,242],"mortality;":[104],"hospitalization":[105],"heart":[107],"failure":[108,115],"(HHF);":[109],"a":[110,188,230],"composite":[111,175],"outcome":[113,177],"(kidney":[114,116],"replacement":[117],"therapy":[118],"or":[119,128,131,213],"persistent":[120],"eGFR":[121,126],"<15":[122],"mL/min/1.73m2),":[123],"sustained":[124],"\u226550%":[125],"decline":[127],"nearest":[129],"equivalent,":[130],"kidney-related":[132],"death);":[133],"worsening":[134],"function;":[136],"safety":[138],"outcomes.":[139],"SYNTHESIS":[141],"Across":[142],"10":[143],"trials":[144],"(n=71,351),":[145],"reduced":[148],"MACE":[149,185],"by":[150,160,167,178,197],"14%":[151,168,190],"(HR":[152,162,169,180],"0.86":[153,170],"[95%":[154],"CI":[155],"0.81-0.90];":[156],"I2=27.6%),":[157],"mortality":[159],"12%":[161],"0.88":[163],"[0.82-0.93];":[164],"I2=17.5%),":[165],"HHF":[166],"[0.79-0.93];":[171],"I2=2.1%),":[172],"17%":[179],"0.83":[181],"[0.75-0.92];":[182],"I2=20.4%).":[183],"All":[184],"components":[186],"showed":[187],"consistent":[189],"reduction.":[191],"There":[192,204],"was":[193],"no":[194,206],"significant":[195],"heterogeneity":[196],"GLP-1RA":[198],"administration":[199],"route":[200],"(subcutaneous":[201],"vs.":[202],"oral).":[203],"were":[205],"increased":[207],"severe":[210],"hypoglycemia,":[211],"retinopathy,":[212],"pancreatic":[214],"events.":[215],"LIMITATIONS":[216],"Trial-level":[217],"meta-analyses":[218],"preclude":[219],"detailed":[220],"subgroup":[221],"analyses":[222],"may":[224],"introduce":[225],"ecological":[226],"bias.":[227],"CONCLUSIONS":[228],"As":[229],"group,":[231],"GLP-1RAs,":[233],"injectable":[236],"formulations,":[239],"MACE,":[241],"mortality,":[243],"HHF,":[244]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2025-03-29T00:00:00"}